Angus Chen is a partner at the New York office of Frommer Lawrence & Haug LLP.
Dr. Chen’s practice focuses on intellectual property litigation, counseling, opinion and agreement work. He specializes in the pharmaceutical patent and regulatory laws under the Hatch-Waxman Amendments to the Federal Food, Drug & Cosmetic Act.
Dr. Chen originally started with the firm as a Scientific Advisor. He then joined Par Pharmaceutical, Inc. a specialty pharmaceutical company that develops, manufactures and markets generic drugs, and branded drugs for specialty markets. Over the course of two and half years, Dr. Chen became in house Patent Counsel and was responsible for managing the company’s intellectual property strategies.
Dr. Chen received a Ph.D. in biochemistry from the Mount Sinai School of Medicine in 2002, where he was awarded a National Cancer Institute training grant. His dissertation research focused on protein degradation pathways underlying cancer, including studies of hereditary breast cancer susceptibility genes.
